Cargando…

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

OBJECTIVES: To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) phase 2b/3 upadacitinib clinical programmes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charles-Schoeman, Christina, Choy, Ernest, McInnes, Iain B, Mysler, Eduardo, Nash, Peter, Yamaoka, Kunihiro, Lippe, Ralph, Khan, Nasser, Shmagel, Anna K, Palac, Hannah, Suboticki, Jessica, Curtis, Jeffrey R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Inflammatory Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649869/ https://www.ncbi.nlm.nih.gov/pubmed/37945286 http://dx.doi.org/10.1136/rmdopen-2023-003392

Ejemplares similares

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
por: Smolen, Josef S, et al.
Publicado: (2019)

Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden
por: Landgren, Anton Jonatan, et al.
Publicado: (2021)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
por: Huss, Viking, et al.
Publicado: (2023)

Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark
por: Secher, Anne Emilie Pape, et al.
Publicado: (2022)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis
por: Pott, Nina Mee, et al.
Publicado: (2022)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
por: Marques, Andréa, et al.
Publicado: (2021)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response
por: Daïen, Claire I, et al.
Publicado: (2015)

Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis
por: Ghosh, Nilasha, et al.
Publicado: (2023)

Allergic conditions and risk of rheumatoid arthritis: a Swedish case–control study
por: Kronzer, Vanessa L, et al.
Publicado: (2022)

It is not just about sex: viewpoints of men with inflammatory arthritis on the overall impact of the disease on their sexual health
por: Perez-Garcia, Luis Fernando, et al.
Publicado: (2021)

Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis
por: Symons, Rebecca A, et al.
Publicado: (2022)

Increased primary care use for musculoskeletal symptoms, infections and comorbidities in the years before the diagnosis of inflammatory arthritis
por: van Beers-Tas, Marian, et al.
Publicado: (2020)

Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility)
por: Perez-Garcia, Luis Fernando, et al.
Publicado: (2021)

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis
por: Cappelli, Laura C, et al.
Publicado: (2022)

Depressive mood and low social support are not associated with arthritis development in patients with seropositive arthralgia, although they predict increased musculoskeletal symptoms
por: Holla, Jasmijn F M, et al.
Publicado: (2018)

TRPA1 expression is downregulated by dexamethasone and aurothiomalate in human chondrocytes: TRPA1 as a novel factor and drug target in arthritis
por: Nummenmaa, Elina, et al.
Publicado: (2017)

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
por: Ladouceur, Alexandra, et al.
Publicado: (2023)

Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis
por: Horton, Sarah C, et al.
Publicado: (2017)

Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe
por: Just, Søren Andreas, et al.
Publicado: (2018)

Young people’s perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force
por: Mosor, Erika, et al.
Publicado: (2021)

Does socioeconomic status make a difference? A register-based study on the extent to which cardiovascular screening in patients with inflammatory arthritis leads to recommended follow-up in general practice
por: Kjeldgaard, Anette Hvenegaard, et al.
Publicado: (2020)

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
por: Fleischmann, Roy, et al.
Publicado: (2022)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
por: Fleischmann, Roy M, et al.
Publicado: (2019)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies
por: Gladman, Dafna D., et al.
Publicado: (2019)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Psoriatic arthritis: an evolving matter
por: Wendling, Daniel
Publicado: (2015)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
por: McInnes, Iain B, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bqdqbl7noev6csnso32tdmep6c